Please assess the completion status of the following clinical trial:

Trial Title: Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients on long-term warfarin (for prophylaxis of arterial embolism in patients with atrial fibrillation or mechanical heart valve replacement, or secondary prophylaxis after VTE) with a target INR of 2.0-3.0 or 2.5-3.5,~* Anticoagulant therapy managed by the clinic (HHS - General Hospital) for at least 6 months prior to enrolment, and~* Maintenance dose of warfarin unchanged for the previous 6 months or longer.~Exclusion Criteria:~* Age \<18 years,~* Life expectancy of less than 1 year,~* Attending physician believes the patient is not suitable for the study (e.g. psychiatric disorder, history of non-compliance),~* Geographic inaccessibility or~* Failure to obtain written consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12-weekly INR (Type: SHAM_COMPARATOR): Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
- Standard management (Type: NO_INTERVENTION): Dosing warfarin every 4 weeks, all INRs true values

Based on this trial design, predict the completion outcome and termination type (if applicable).